The FDA has granted fast track and rolling review status to Celltrion’s CT-P71, a Nectin-4 targeting ADC for treating ...
Less than half of Australians diagnosed with rare cancers survive five years after diagnosis, with advocates calling on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results